Arrhythmogenic Right Ventricular Cardiomyopathy

1. Clinical Overview

Summary

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined cardiomyopathy characterized by progressive replacement of ventricular myocardium with fibrofatty tissue, predisposing to life-threatening ventricular arrhythmias and sudden cardiac death (SCD), particularly in young individuals and athletes. [1,2]

The disease predominantly affects the right ventricle, though left ventricular and biventricular involvement is increasingly recognized. ARVC is caused primarily by mutations in genes encoding desmosomal proteins, which maintain intercellular connections in cardiac myocytes. [3,4] The resulting structural abnormalities create an arrhythmogenic substrate leading to ventricular tachycardia (VT) with characteristic left bundle branch block (LBBB) morphology.

ARVC is a leading cause of sudden cardiac death in young adults (age less than 35 years) and competitive athletes, accounting for up to 11% of sudden deaths in this population. [5] The estimated prevalence is 1:2000 to 1:5000, with autosomal dominant inheritance and variable penetrance. [6]

Key Facts

• Prevalence: 1:2000-1:5000 in general population; higher in athletic cohorts [6]
• Inheritance: Autosomal dominant with incomplete penetrance (30-50%)
• Peak presentation: 20-40 years (young adults)
• Genetics: 50-60% have identifiable desmosomal mutations (PKP2, DSG2, DSP, DSC2, JUP) [3,4]
• SCD risk: 5-10% without treatment; less than 1% with appropriate ICD therapy [7]
• Diagnostic criteria: 2010 Task Force Criteria (updated 2023) [8,9]
• Gold standard imaging: Cardiac MRI with tissue characterization [10]

Clinical Pearls

"Think ARVC in young athletes with VT" — ARVC is a leading cause of SCD in competitive athletes and should be considered in any young person presenting with VT of LBBB morphology, particularly if exercise-induced. [5,11]

"Epsilon wave = major ECG criterion" — The epsilon wave (reproducible low-amplitude signals between the end of QRS and onset of T wave in leads V1-V3) is pathognomonic for ARVC, present in 30-50% of cases and represents delayed RV depolarization. [12,13]

"Desmosomal disease accelerated by exercise" — Endurance exercise accelerates disease progression in ARVC patients and genotype-positive family members; exercise restriction is therapeutic, not just preventive. [14,15]

"ICD saves lives, but choose wisely" — ICD implantation reduces SCD risk dramatically, but appropriate patient selection using risk stratification is essential to balance benefit versus complications. [7,16]

Why This Matters Clinically

ARVC represents a critical diagnosis that must not be missed in young patients presenting with palpitations, syncope, or cardiac arrest. Early diagnosis through systematic application of diagnostic criteria, aggressive risk stratification, and appropriate intervention with ICD therapy can prevent sudden cardiac death. Family screening is essential as first-degree relatives have a 50% chance of carrying the mutation. The disease is progressive, and lifestyle modification (particularly exercise restriction) is an important therapeutic intervention that can modify disease course. [14,15,17]

---

2. Epidemiology

Incidence & Prevalence

• General population: 1:2000 to 1:5000 [6]
• Athlete population: Higher prevalence; accounts for 11-22% of SCD in young athletes [5,11]
• Geographic variation: Higher prevalence in regions of Italy (Veneto region: 1:1000) [18]
• Increasing recognition: Prevalence estimates rising due to improved diagnostic criteria and imaging techniques [8,9]

Demographics

Risk Factors

Non-Modifiable:

Modifiable:

Common Presentations

---

3. Aetiology & Pathophysiology

Genetic Basis

Desmosomal Genes (85-90% of identifiable mutations): [3,4,20]

Non-Desmosomal Genes (10-15% of identifiable mutations):

• TMEM43: Highly malignant form, fully penetrant in males [21]
• PLN (phospholamban): Associated with dilated cardiomyopathy-like phenotype
• DES (desmin), LMNA (lamin A/C): Rare, associated with skeletal myopathy

Inheritance Pattern:

• Autosomal dominant with incomplete penetrance (30-50%)
• Age-dependent penetrance (increases with age)
• Variable expressivity (wide phenotypic spectrum even within families)
• Compound heterozygosity or digenic inheritance associated with severe phenotype [20]

Molecular Pathophysiology

Step 1: Desmosomal Dysfunction [4,20]

Desmosomes are specialized cell-cell adhesion structures critical for mechanical coupling between cardiac myocytes. Mutations in desmosomal proteins lead to:

• Impaired mechanical coupling between myocytes
• Disruption of the desmosome-cytoskeleton interface
• Defective signal transduction (Wnt/β-catenin pathway suppression)

Step 2: Myocyte Death and Replacement

Progressive myocyte loss occurs through:

• Mechanical stress-induced myocyte apoptosis
• Inflammatory response and myocarditis-like injury
• Replacement fibrosis and adipogenesis
• Preferential RV involvement due to thinner wall, higher wall stress

Step 3: Arrhythmogenic Substrate Formation

Fibro-fatty replacement creates:

• Slow conduction zones (substrate for reentrant arrhythmias)
• Electrical heterogeneity and dispersion of refractoriness
• Triggered activity from surviving myocytes embedded in fibrosis
• VT circuits typically involving the "triangle of dysplasia" (RV inflow tract, outflow tract, apex)

Step 4: Exercise-Induced Acceleration [14,15]

Endurance exercise accelerates disease through:

• Increased mechanical stress on genetically vulnerable myocardium
• Elevated catecholamines triggering arrhythmias
• Chronic volume overload promoting RV dilation
• Dose-dependent relationship between exercise volume and disease progression

Step 5: Progressive Heart Failure

Advanced disease leads to:

• RV dilation and systolic dysfunction
• Tricuspid regurgitation (annular dilation)
• Left ventricular involvement (30-76% of cases) [22]
• Biventricular failure in advanced stages

Disease Stages (Natural History)

---

4. Clinical Presentation

Symptoms: The Patient's Story

Cardinal Symptoms:

1. Palpitations (60-70%)

   • Often exercise-induced or post-exertion
   • May describe rapid regular heart rate (VT) or irregular rhythm (frequent PVCs)
   • Can be associated with presyncope

2. Syncope (25-35%)

   • Typically exertional or immediately post-exercise
   • May be preceded by palpitations
   • Arrhythmic in origin (distinguishes from vasovagal)
   • HIGH RISK FEATURE requiring urgent evaluation

3. Sudden Cardiac Arrest (15-25%)

   • May be first presentation
   • Often during or immediately after vigorous exercise
   • VF or rapid polymorphic VT as mechanism
   • Resuscitated SCD = Class I indication for ICD

4. Dyspnea/Exercise Intolerance

   • Initially only with extreme exertion
   • Progressive with RV dysfunction
   • Orthopnea/PND if biventricular involvement

5. Chest Pain

   • Atypical, non-exertional
   • May mimic pericarditis
   • Mechanism unclear (microinfarction vs arrhythmia)

Red Flag History:

[!CAUTION] RED FLAGS — Immediate Cardiology Referral:

• Syncope during or immediately after exercise
• Resuscitated cardiac arrest
• Sustained VT (≥30 seconds)
• Unexplained syncope with family history of SCD
• Symptoms developing in context of intensive athletic training

Family History (ESSENTIAL to elicit):

• Sudden cardiac death less than 35 years (particularly during exertion)
• Known ARVC diagnosis in relatives
• Unexplained drowning or motor vehicle accidents (possible arrhythmic deaths)
• ICD implantation in young relatives
• Consanguinity (increases risk of homozygous/compound heterozygous mutations)

Exercise History:

• Type: Endurance sports (running, cycling, rowing) highest risk [14,15]
• Duration: Cumulative years of training
• Intensity: High-intensity interval training, competitive level
• Volume: Quantify in hours/week or METs-minutes/week
• Timing of symptoms: During, immediately post, or remote from exercise

Signs: What You Find

General Appearance:

• Usually normal at rest unless advanced disease
• May appear anxious if symptomatic arrhythmia
• Signs of heart failure if RV/biventricular dysfunction

Vital Signs:

Cardiovascular Examination:

Examination Pearls:

• Examination often completely normal in concealed or early overt stage
• Arrhythmias may be provoked by exercise (consider exercise testing)
• Look for extracardiac features: palmoplantar keratoderma, woolly hair (Naxos/Carvajal syndrome)

---

5. Differential Diagnosis

Must-Not-Miss Diagnoses

1. Cardiac Sarcoidosis [23]

• Key distinguishing features:
  • Systemic features (pulmonary, skin, eyes)
  • PET-FDG uptake on imaging
  • Typically patchy LV involvement (not RV-predominant)
  • Late gadolinium enhancement in basal septum (not RV free wall)
  • Elevation in ACE, lysozyme
• Why important: Requires immunosuppression; ICD indications differ

2. Acute Myocarditis

• Key distinguishing features:
  • Acute presentation with viral prodrome
  • Troponin elevation
  • Usually global dysfunction, not regional
  • May improve with supportive care
  • No family history
• Why important: Different prognosis; may be fulminant but potentially reversible

3. Idiopathic VT from RVOT

• Key distinguishing features:
  • Structurally normal heart
  • VT typically adenosine/verapamil-sensitive
  • Excellent prognosis
  • No progression
• Why important: Benign condition; ablation curative

Other Important Differentials

---

6. Investigations

Diagnostic Approach

ARVC diagnosis is based on the 2010 revised Task Force Criteria (updated 2023), integrating multiple modalities. [8,9] Diagnosis requires:

• 2 major criteria, OR
• 1 major + 2 minor criteria, OR
• 4 minor criteria from different categories

First-Line Investigations

1. 12-Lead ECG (Essential) [8,12,13]

Major ECG Criteria:

• Epsilon wave in right precordial leads (V1-V3) — pathognomonic
  • Low-amplitude signals between QRS and T wave
  • Represents delayed RV activation through fibrotic tissue
  • Present in 30-50% of ARVC cases
  • Best seen with high-pass filter at 40 Hz, increased gain

Minor ECG Criteria:

• T wave inversion in V1-V3 (in absence of RBBB) in individuals > 14 years
• Late potentials on signal-averaged ECG (SAECG)
• Terminal activation duration ≥55 ms from nadir of S wave to end of QRS in V1-V3

Additional ECG Findings (not in criteria):

• Frequent PVCs (> 500/24h) with LBBB morphology
• Prolonged QRS duration in V1-V3
• QRS dispersion ≥40 ms
• QTc prolongation

2. Holter Monitor / Ambulatory ECG

Major Arrhythmia Criterion:

• Non-sustained or sustained VT with LBBB morphology and superior axis

Minor Arrhythmia Criterion:

• Non-sustained or sustained VT with LBBB morphology and inferior axis

• 500 PVCs per 24 hours

Interpretation:

• LBBB morphology confirms RV origin
• Superior axis suggests RV outflow tract origin (more specific for ARVC)
• Inferior axis less specific (may be RVOT idiopathic VT)

3. Echocardiography [8,10]

Major Criteria:

• Regional RV akinesia, dyskinesia, or aneurysm PLUS one of:
  • "RVOT PLAX ≥32 mm (corrected for BSA: ≥19 mm/m²)"
  • "RVOT PSAX ≥36 mm (corrected for BSA: ≥21 mm/m²)"
  • RV fractional area change ≤33%

Minor Criteria:

• Regional RV akinesia or dyskinesia PLUS one of:
  • RVOT PLAX ≥29-31 mm (corrected ≥16-18 mm/m²)
  • RVOT PSAX ≥32-35 mm (corrected ≥18-20 mm/m²)
  • RV fractional area change > 33-40%

Echo Pearls:

• RV is difficult to image; dedicated RV views essential
• Look for regional wall motion abnormalities (WMA) — more specific than global dilation
• Subtricuspid region, RV outflow tract, apex ("triangle of dysplasia") commonly affected
• Trabecular disarray and increased trabeculation may be seen

Second-Line/Gold Standard Investigations

4. Cardiac MRI (Gold Standard for Structure) [10,24]

Why MRI is superior:

• Tissue characterization: fat detection, fibrosis quantification
• Superior RV imaging compared to echo
• Quantitative RV volumes and function
• Detection of LV involvement

Major MRI Criteria:

• Regional RV akinesia, dyskinesia, or dyssynchrony PLUS one of:
  • RV EDV/BSA ≥110 mL/m² (male) or ≥100 mL/m² (female)
  • RV ejection fraction ≤40%

Minor MRI Criteria:

• Regional RV akinesia, dyskinesia, or dyssynchrony PLUS one of:
  • RV EDV/BSA ≥100-109 mL/m² (male) or 90-99 mL/m² (female)
  • RV ejection fraction 41-45%

Late Gadolinium Enhancement (LGE):

• Detects myocardial fibrosis
• Typical pattern: RV free wall, particularly subepicardial
• LGE extent correlates with arrhythmic risk
• Presence of LV LGE indicates biventricular involvement

Tissue Characterization:

• T1-weighted imaging: fat detection (hyperintense signal)
• CAUTION: Intramyocardial fat is NOT specific; can be seen in normal individuals, athletes, obesity
• Must correlate with wall motion abnormalities and other criteria
• T1 mapping: detect diffuse fibrosis

MRI Pitfalls:

• High false-positive rate if fat alone used as criterion
• Requires experienced cardiac imager
• Contraindicated if ICD in situ (unless MRI-conditional device)

5. Genetic Testing [3,4,20]

Major Genetic Criterion:

• Pathogenic or likely pathogenic ARVC-causative mutation

Minor Genetic Criterion:

• Variant of uncertain significance (VUS) in ARVC gene

Panel Testing:

• Test for: PKP2, DSG2, DSP, DSC2, JUP, TMEM43, PLN, DES, LMNA
• Yield: 50-60% will have identifiable mutation
• Negative genetic test does NOT exclude ARVC (incomplete sensitivity)

Clinical Utility:

• Confirms diagnosis in borderline cases
• Enables cascade family screening (test relatives for specific familial mutation)
• Prognostic: certain mutations (DSP, TMEM43) carry higher SCD risk
• Pre-test genetic counseling essential

6. Endomyocardial Biopsy (Rarely Performed)

Major Histological Criterion:

• Residual myocytes less than 60% by morphometric analysis (or less than 50% if estimated)
• Fibrofatty replacement of RV free wall myocardium

Indications:

• Rarely needed (high false-negative rate due to patchy involvement)
• Consider if diagnosis uncertain and other tests non-diagnostic
• Risk of RV perforation

7. Family History [8]

Major Family History Criterion:

• ARVC confirmed in first-degree relative who meets TFC
• ARVC confirmed pathologically at autopsy or surgery in first-degree relative
• Identification of pathogenic mutation categorized as associated or probably associated with ARVC in patient under evaluation

Minor Family History Criterion:

• History of ARVC in first-degree relative in whom it is not possible to determine whether criteria are fulfilled
• Premature sudden death (less than 35 years) due to suspected ARVC in first-degree relative
• ARVC confirmed pathologically or by current TFC in second-degree relative

Risk Stratification Investigations

Exercise Testing:

• Unmask exercise-induced arrhythmias
• Assess chronotropic competence
• VT induction = high-risk feature

Electrophysiology Study (EPS):

• Not routine
• Consider if: unexplained syncope, risk stratification pre-ICD decision
• Inducibility of sustained VT/VF = high risk marker [16]

---

7. Diagnosis & Classification

2010 Task Force Criteria (TFC) Summary [8]

Diagnosis requires:

• 2 major, OR
• 1 major + 2 minor, OR
• 4 minor criteria (from different categories)

Categories:

1. Structural (imaging: echo, MRI, angiography, histology)
2. Tissue characterization (fibrofatty replacement)
3. Repolarization (ECG: T wave inversion)
4. Depolarization (epsilon wave, terminal activation delay, SAECG late potentials)
5. Arrhythmias (VT, PVCs)
6. Family history
7. Genetic testing

2023 Padua Criteria (Emerging) [9]

Updated criteria recognize:

• Arrhythmogenic Cardiomyopathy (ACM) encompasses ARVC, left-dominant, and biventricular forms
• Broader phenotypic spectrum beyond classic RV-predominant disease
• Enhanced role for advanced imaging (MRI tissue characterization)
• Integration of genetic data

Diagnostic Challenges

Borderline/"Possible" ARVC:

• Fulfills some but not full TFC
• Consider: serial imaging, family screening, genetic testing
• Close follow-up essential

Diagnostic Pitfalls:

• Athlete's heart vs early ARVC: ECG changes (TWI) can overlap
• Idiopathic RVOT VT vs ARVC: both have LBBB-VT, but RVOT-VT has structurally normal heart
• Acute myocarditis vs ARVC: both can have RV involvement, troponin elevation

---

8. Management

Management Algorithm

SUSPECTED ARVC
(Young person + VT/syncope/family history)
            ↓
┌──────────────────────────────────────────────┐
│ COMPREHENSIVE EVALUATION                     │
│ • 12-lead ECG (look for epsilon wave, TWI)   │
│ • Holter monitor (24-48h, look for VT/PVCs)  │
│ • Echocardiography (RV size, function, WMA)  │
│ • Cardiac MRI (tissue characterization, LGE) │
│ • Exercise test (arrhythmia provocation)     │
│ • Genetic testing (desmosomal gene panel)    │
│ • Detailed family history (3 generations)    │
└──────────────────────────────────────────────┘
            ↓
┌──────────────────────────────────────────────┐
│ DIAGNOSIS CONFIRMED (2010 TFC MET)           │
│ • Apply diagnostic criteria systematically   │
│ • Document major/minor criteria met          │
│ • Confirm with cardiology/EP specialist      │
└──────────────────────────────────────────────┘
            ↓
┌──────────────────────────────────────────────┐
│ RISK STRATIFICATION FOR SCD                  │
│ HIGH RISK (Class I/IIa ICD indication):      │
│ • Cardiac arrest survivor                    │
│ • Sustained VT (spontaneous)                 │
│ • Syncope (unexplained, likely arrhythmic)   │
│ • Severe RV/LV dysfunction (EF less than 35%)         │
│ • Inducible VT/VF at EPS                     │
│ • Extensive LGE on MRI                       │
│ LOWER RISK (individualize):                  │
│ • Non-sustained VT                           │
│ • Frequent PVCs (> 1000/24h)                  │
│ • Moderate RV dysfunction                    │
└──────────────────────────────────────────────┘
            ↓
┌──────────────────────────────────────────────┐
│ PREVENT SUDDEN CARDIAC DEATH                 │
│ PRIMARY PREVENTION ICD:                      │
│ • Class IIa: Syncope, severe dysfunction,    │
│   extensive disease, high-risk genotype      │
│ • Consider: 5-year VT/VF risk > 10%           │
│ SECONDARY PREVENTION ICD:                    │
│ • Class I: Cardiac arrest, sustained VT      │
│ • Essential life-saving intervention         │
└──────────────────────────────────────────────┘
            ↓
┌──────────────────────────────────────────────┐
│ MEDICAL THERAPY                              │
│ • Beta-blockers: All patients (Class I)      │
│ • Antiarrhythmics: If recurrent VT           │
│   - Sotalol first-line (if QTc normal)       │
│   - Amiodarone if sotalol inadequate         │
│ • Heart failure therapy: If LV/RV dysfunction│
│   - ACE-I/ARB, aldosterone antagonist        │
│   - Diuretics if fluid overload              │
└──────────────────────────────────────────────┘
            ↓
┌──────────────────────────────────────────────┐
│ CATHETER ABLATION                            │
│ INDICATIONS:                                 │
│ • Recurrent VT despite medical therapy       │
│ • Frequent ICD shocks (≥2 appropriate)       │
│ • VT storm                                   │
│ • Monomorphic VT (ablatable circuit)         │
│ APPROACH: Epicardial + endocardial mapping   │
│ SUCCESS: 60-80% VT-free at 1 year            │
│ LIMITATION: Disease progression continues    │
└──────────────────────────────────────────────┘
            ↓
┌──────────────────────────────────────────────┐
│ EXERCISE RESTRICTION (CLASS I)               │
│ ALL ARVC PATIENTS:                           │
│ • Avoid competitive sports (disqualifying)   │
│ • Restrict vigorous endurance exercise       │
│ • Limit to moderate intensity recreational   │
│ • less than 2000 MET-min/week recommended             │
│ GENOTYPE-POSITIVE/PHENOTYPE-NEGATIVE:        │
│ • Exercise restriction still recommended     │
│ • Delays disease onset, reduces penetrance   │
│ EVIDENCE: Reduces VT burden, slows progression│
└──────────────────────────────────────────────┘
            ↓
┌──────────────────────────────────────────────┐
│ FAMILY SCREENING (CLASS I)                   │
│ FIRST-DEGREE RELATIVES:                      │
│ • Clinical evaluation (ECG, echo, Holter)    │
│ • Cardiac MRI if available                   │
│ • Genetic testing if proband mutation known  │
│ • Serial screening every 2-5 years           │
│ GENETIC CASCADE SCREENING:                   │
│ • Test relatives for familial mutation       │
│ • Discharge if gene-negative (no follow-up)  │
│ • Monitor gene-positive (penetrance risk)    │
└──────────────────────────────────────────────┘
            ↓
┌──────────────────────────────────────────────┐
│ LONG-TERM MONITORING                         │
│ SERIAL IMAGING: Every 1-3 years              │
│ • Track RV/LV function progression           │
│ • Assess for LV involvement                  │
│ ICD SURVEILLANCE: Every 3-6 months           │
│ • Check battery, lead integrity              │
│ • Interrogate for arrhythmias, shocks        │
│ HOLTER MONITORING: Annually                  │
│ • Assess arrhythmic burden                   │
│ • Guide antiarrhythmic therapy               │
└──────────────────────────────────────────────┘

Acute/Emergency Management

Sustained VT (Hemodynamically Unstable):

1. Immediate DC cardioversion (synchronized 100-200J biphasic)
2. Amiodarone loading: 150 mg IV over 10 min, then 1 mg/min × 6h, then 0.5 mg/min
3. Beta-blocker: Metoprolol 5 mg IV q5min × 3 (if hemodynamically tolerated)
4. Admit to CCU/telemetry
5. Urgent cardiology/EP consult for risk stratification and ICD consideration

Sustained VT (Hemodynamically Stable):

1. Medical cardioversion: Amiodarone 150 mg IV over 10 min
2. Beta-blocker: Metoprolol 5 mg IV
3. If fails: Consider electrical cardioversion
4. Admit for monitoring

VT Storm (≥3 episodes VT in 24h):

1. Deep sedation (reduce sympathetic drive)
2. Amiodarone loading + beta-blockade
3. Urgent catheter ablation (within 24-48h if refractory)
4. Hemodynamic support if needed (inotropes, mechanical support)
5. EP consultation emergent

Cardiac Arrest:

1. Standard ACLS resuscitation
2. Post-ROSC care: Hemodynamic stabilization, neuroprotection
3. ICD implantation: Class I indication (secondary prevention)
4. Coronary angiography: Exclude acute coronary syndrome
5. Amiodarone: Suppressive therapy until ICD implanted

Medical Management

Beta-Blockers (Class I Recommendation for ALL Patients):

Mechanism: Reduce adrenergic triggers for VT; slow VT rate; reduce exercise-induced arrhythmias Evidence: Reduces VT burden in observational studies; no RCTs but consensus Class I recommendation

Antiarrhythmic Drugs (for Recurrent VT):

Combination Therapy:

• Beta-blocker + sotalol: Synergistic effect
• Beta-blocker + amiodarone: For refractory VT
• NEVER flecainide alone (risk of 1:1 atrial flutter with rapid conduction)

Heart Failure Therapy (if LVEF less than 40% or symptomatic RV failure):

• ACE inhibitors (or ARB): Ramipril 2.5-10 mg daily, Enalapril 2.5-20 mg BD
• Beta-blockers: As above (dual indication)
• Aldosterone antagonists: Spironolactone 25-50 mg daily (if LVEF less than 35%)
• Diuretics: Furosemide, titrate to euvolemia
• Advanced therapies: Heart transplantation for end-stage biventricular failure

Device Therapy: ICD Implantation [7,16,25]

Class I Indications (Definite Benefit):

1. Secondary prevention:

   • Cardiac arrest due to VT/VF (not due to reversible cause)
   • Sustained VT (> 30s or hemodynamically unstable)

2. Primary prevention (high-risk features):

   • Severe RV dysfunction (RVEF less than 35%) or severe LV dysfunction (LVEF less than 35%)
   • Syncope with documented VT/VF on monitoring

Class IIa Indications (Probable Benefit):

1. Extensive disease (multiple structural abnormalities)
2. One or more affected family members with SCD
3. Unexplained syncope (when VT/VF suspected)
4. Non-sustained VT on Holter + inducible sustained VT at EPS

Class IIb Indications (Consider):

1. Frequent PVCs (> 1000/24h) + moderate RV dysfunction
2. Genotype-positive with high-risk mutation (TMEM43-p.S358L, certain DSP mutations)

Risk Stratification Tools:

5-Year VT/VF Risk Calculator (Cadrin-Tourigny et al., 2019): [16]

• Incorporates: age, sex, recent cardiac syncope, NSVT, PVC count, number of TWI leads, RV/LVEF
• Estimates 5-year risk of sustained VT/VF
• Risk > 10% at 5 years often used as ICD threshold

Device Selection:

• Transvenous ICD: Standard approach
• Subcutaneous ICD (S-ICD): Consider in young patients (avoid lead complications); no pacing/ATP capability
• CRT-D (biventricular ICD): If LVEF less than 35% + QRS ≥120 ms + heart failure symptoms

ICD Programming:

• Long detection times (reduce inappropriate shocks)
• Antitachycardia pacing (ATP) before shock for VT
• Avoid single-chamber detection enhancements (risk of T wave oversensing)

Outcomes with ICD: [7]

• SCD mortality reduced from 5-10% to less than 1% per year
• 20-30% receive appropriate shocks over 5 years
• Inappropriate shock rate: 10-20% (often AF, sinus tachycardia, lead issues)

Catheter Ablation [26]

Indications:

• Recurrent VT despite medical therapy (≥2 episodes requiring cardioversion or ICD shock)
• VT storm (≥3 VT episodes in 24h)
• Frequent ICD shocks affecting quality of life
• Incessant VT

Approach:

• Mapping: Endocardial + epicardial substrate mapping (fibro-fatty areas, late potentials)
• Target: Critical VT isthmus, areas of abnormal electrograms
• Energy: Radiofrequency ablation; cryoablation alternative
• Access: Percutaneous epicardial approach often required (RV free wall involvement)

Outcomes:

• VT-free survival: 60-80% at 1 year
• Recurrence common due to disease progression
• Not curative; adjunct to ICD + medical therapy

Complications:

• Cardiac perforation/tamponade (3-5%, higher with epicardial approach)
• Phrenic nerve injury
• Coronary artery injury
• AV block (rare)

Exercise Restriction [14,15,17]

Recommendations (Class I - Mandatory):

Specific Guidelines:

• Disqualifying: All competitive sports (Bethesda Conference recommendations)
• Permitted: Low-moderate intensity recreational exercise (walking, golf, doubles tennis, recreational cycling)
• Quantitative limit: less than 2000 MET-minutes/week (e.g., 30 min moderate activity 3x/week)
• Avoid: Endurance sports (marathons, triathlons, competitive cycling), high-intensity interval training

Evidence for Exercise Restriction: [14,15]

• Wang et al., 2018: Exercise restriction reduced VT risk by 38% in ARVC patients
• Wang et al., 2020: Exercise restriction in genotype-positive family members reduced penetrance and delayed phenotype
• Dose-dependent: Higher exercise volumes associated with earlier disease onset, more severe phenotype, higher arrhythmic burden

Athlete's Dilemma:

• Diagnosis = career-ending for competitive athletes
• Psychological support essential
• Shared decision-making; explain rationale clearly
• Alternative low-risk activities encouraged

Family Screening [6,17]

Who to Screen:

• Mandatory: All first-degree relatives (parents, siblings, children)
• Consider: Second-degree relatives if no first-degree cascade possible

Screening Protocol:

1. Initial evaluation (all first-degree relatives):

   • Detailed history (symptoms, exercise history)
   • 12-lead ECG
   • Echocardiography
   • Holter monitor (24h)
   • Cardiac MRI (if available resources)

2. Genetic testing (if proband mutation known):

   • Test relatives for familial mutation
   • If gene-negative → discharge (no further follow-up needed)
   • If gene-positive → serial monitoring (penetrance surveillance)

3. Serial monitoring (if initial screen negative or gene-positive/phenotype-negative):

   • Repeat clinical evaluation every 2-5 years (more frequent if high-risk genotype)
   • Adjust frequency based on age (penetrance increases with age up to 50-60 years)

Genetic Cascade Screening:

• Advantage: Efficiently identifies at-risk relatives; discharges gene-negative individuals
• Yield: ~50% of relatives carry mutation (autosomal dominant)
• Counseling: Pre-test and post-test genetic counseling essential
• Implications: Insurance, employment, psychological impact

Pediatric Screening:

• Begin screening in adolescence (age 10-12 years)
• Earlier if symptoms or high-risk family history
• Challenging: TWI can be normal in children less than 14 years

---

9. Complications

Arrhythmic Complications

Heart Failure Progression

Right Ventricular Failure:

• Incidence: 10-20% develop overt RV failure
• Symptoms: Peripheral edema, hepatic congestion, ascites
• Hemodynamics: Elevated CVP, low cardiac output
• Management: Diuretics, neurohormonal antagonists

Biventricular Failure:

• Incidence: 30-76% have LV involvement at some stage [22]
• Prognosis: Worse than isolated RV disease
• Management: Standard heart failure therapy; transplant evaluation if advanced

End-Stage Disease:

• Heart transplantation: Consider if EF less than 30%, NYHA III-IV despite optimal therapy
• Mechanical circulatory support: Bridge to transplant
• Outcomes post-transplant: Good (no disease in transplanted heart)

Device-Related Complications

ICD Complications:

• Inappropriate shocks: 10-20% over 5 years (AF, SVT, T wave oversensing)
• Lead fracture/malfunction: Higher in young, active patients; consider S-ICD
• Infection: 1-2% (may require system extraction)
• Psychological impact: Anxiety, depression post-shock

---

10. Prognosis & Outcomes

Natural History (Untreated)

• SCD risk: 5-10% per year in high-risk patients
• Disease progression: Inevitable; RV → LV involvement over time
• Heart failure: 10-30% develop overt HF within 10 years

Outcomes with Contemporary Management [7,17]

Prognostic Factors

Poor Prognosis:

• Proband status (vs family-screened): Symptomatic presentation worse
• Syncope: High-risk marker for SCD
• Cardiac arrest survivor: Indicates malignant substrate
• Extensive RV/LV involvement: Severe structural disease
• LV involvement (LVEF less than 50%): Biventricular worse than isolated RV
• Inducible VT/VF at EPS: Arrhythmogenic substrate
• High-risk genotype: TMEM43-p.S358L (male penetrance ~100%, fulminant), certain DSP mutations
• Extensive fibrosis on MRI (LGE): Larger substrate for VT

Better Prognosis:

• Family-screened (asymptomatic at diagnosis)
• Early diagnosis before symptoms
• Exercise restriction compliance
• ICD implantation (primary prevention)
• Gene-negative (if meets clinical TFC, may have better prognosis than some genotypes)

Quality of Life

• ICD shocks: Major impact on QoL; psychological support essential
• Exercise restriction: Significant for athletes; career-ending
• Anxiety/depression: Common; screen regularly
• Support groups: ARVC patients benefit from peer support

---

11. Evidence & Guidelines

Key Guidelines

1. 2015 ESC Guidelines on Ventricular Arrhythmias and Prevention of SCD [27]

• Comprehensive guidance on risk stratification in ARVC
• ICD indications: Class I for cardiac arrest, sustained VT; Class IIa for high-risk primary prevention
• Exercise restriction: Class I recommendation (avoid competitive sports)
• Evidence Level: IC

2. 2019 HRS Expert Consensus on Arrhythmogenic Cardiomyopathy [17]

• Comprehensive contemporary review
• Risk stratification strategies
• Exercise restriction recommendations
• Family screening protocols
• Evidence Level: Expert consensus

3. 2010 Revised Task Force Criteria for ARVC Diagnosis [8]

• Diagnostic standard (major/minor criteria)
• Improved sensitivity vs 1994 criteria (especially for familial disease)
• Integrates imaging, ECG, arrhythmia, genetics, family history, histology
• Evidence Level: Expert consensus

4. 2023 European Task Force Criteria (Padua Criteria) [9]

• Updated diagnostic framework
• Recognizes broader "Arrhythmogenic Cardiomyopathy" spectrum
• Enhanced role for MRI tissue characterization
• Evidence Level: Expert consensus (emerging)

Landmark Studies

1. Marcus et al., 2010: Revised Task Force Criteria [8]

• PMID: 20172911
• Established current diagnostic standard
• Improved sensitivity for familial/early disease

2. Corrado et al., 2017: Arrhythmogenic Cardiomyopathy Review [2]

• PMID: 28912183
• Comprehensive pathophysiology, genetics, management review

3. Cadrin-Tourigny et al., 2019: 5-Year VT/VF Risk Prediction [16]

• PMID: 31387592
• Developed and validated risk calculator for SCD
• Helps guide ICD decision-making

4. Wang et al., 2018: Exercise Restriction Impact [14]

• PMID: 29909402
• Demonstrated 38% reduction in VT with exercise restriction
• First robust evidence for exercise as therapeutic intervention

5. Wang et al., 2020: Exercise Restriction in Genotype-Positive [15]

• PMID: 32572458
• Showed exercise restriction delays phenotype in gene carriers
• Supports prophylactic exercise restriction

6. Zorzi et al., 2016: ICD Risk Stratification Review [25]

• PMID: 27147509
• Comprehensive review of risk factors for SCD
• ICD indication framework

Evidence Strength Summary

---

12. Patient/Layperson Explanation

What is ARVC?

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease where normal heart muscle cells are gradually replaced by scar tissue and fat. This replacement happens mainly in the right side of your heart (right ventricle), though it can also affect the left side.

Think of your heart muscle as a strong, electrically active tissue that pumps blood. In ARVC, some of this muscle is replaced by fat and scar tissue, which:

• Weakens the heart wall (making it harder to pump blood effectively)
• Creates electrical problems (causing dangerous fast heart rhythms called ventricular tachycardia)
• Can lead to sudden cardiac arrest (the most serious complication)

Key point: ARVC is a genetic condition passed down in families. If you have it, there's a 50% chance each of your children will inherit the gene mutation.

Why does it matter?

ARVC is a leading cause of sudden cardiac death in young people and athletes. Without treatment, 5-10% of people with ARVC die suddenly each year, often during or just after exercise. The good news? With proper treatment—especially an implantable cardioverter-defibrillator (ICD)—this risk drops to less than 1% per year.

Early diagnosis saves lives. If ARVC is recognized early, we can:

• Prevent sudden death with an ICD (a device that shocks your heart if it develops a dangerous rhythm)
• Slow disease progression with exercise restriction and medications
• Screen your family members (who may also be at risk)

How is it diagnosed?

Diagnosing ARVC requires multiple tests, because no single test is perfect:

1. ECG (electrocardiogram): May show a characteristic finding called an "epsilon wave" (a tiny extra wave on the ECG) or inverted T waves in certain leads

2. Holter monitor (24-48 hour heart monitor): Detects abnormal heart rhythms, especially ventricular tachycardia (VT) or frequent extra beats (PVCs) coming from the right ventricle

3. Echocardiogram (ultrasound of the heart): Shows if the right ventricle is enlarged, has weak areas, or isn't pumping well

4. Cardiac MRI (magnetic resonance imaging): The best test for seeing structural changes. Can detect:

   • Fat infiltration in the heart muscle
   • Scar tissue (shown by "late gadolinium enhancement")
   • Right ventricle size and function

5. Genetic testing: A blood test that looks for mutations in genes that cause ARVC (found in about 50-60% of patients). Useful for confirming diagnosis and testing family members.

Diagnosis requires meeting specific "Task Force Criteria"—a combination of abnormal findings on these tests.

How is it treated?

Treatment focuses on preventing sudden death and managing symptoms:

1. ICD (Implantable Cardioverter-Defibrillator) — The Most Important Treatment

• What it is: A small device implanted under the skin near your collarbone, connected to wires (leads) that go into your heart
• What it does: Constantly monitors your heart rhythm. If it detects a dangerous fast rhythm (VT or VF), it delivers an electric shock to restore normal rhythm
• Who needs it:
  • "Definitely: If you've had cardiac arrest or sustained VT (Class I indication—meaning essential)"
  • "Probably: If you have high-risk features like severe heart dysfunction, unexplained fainting, or family history of sudden death (Class IIa)"
• How well it works: Reduces sudden death risk from 5-10% to less than 1% per year—it's life-saving
• What to expect: Most people never get shocked (the ICD is "insurance"). If you do get shocked, it feels like being kicked in the chest, but it saved your life. Some people get shocked inappropriately (for fast but non-dangerous rhythms)—this can be reduced with proper device programming.

2. Medications

Beta-Blockers (e.g., nadolol, metoprolol):

• Everyone with ARVC should take a beta-blocker
• Purpose: Reduces the heart rate and makes dangerous rhythms less likely
• Dose: Adjusted to keep your resting heart rate around 55-65 beats per minute

Antiarrhythmic Drugs (e.g., sotalol, amiodarone):

• Who needs them: If you have recurrent VT despite a beta-blocker, or if you're getting frequent ICD shocks
• Purpose: Suppresses abnormal rhythms
• Monitoring: Sotalol requires checking your QTc interval (can prolong it); amiodarone requires thyroid, liver, and lung monitoring every 6-12 months

Heart Failure Medications (if needed):

• If your heart's pumping function is weak, you may need ACE inhibitors, diuretics, or other heart failure drugs

3. Catheter Ablation

• What it is: A procedure where a doctor threads catheters (thin tubes) into your heart and uses radiofrequency energy to destroy the areas causing VT
• Who needs it: If you have frequent VT despite medications, or frequent ICD shocks
• Success rate: 60-80% are free of VT one year later, but recurrence is common because the underlying disease continues to progress
• Not a cure: Ablation is an additional treatment, not a replacement for an ICD

4. Exercise Restriction — Critical for Slowing Disease

Why it matters: Exercise accelerates ARVC. Studies show that:

• Athletes with ARVC develop symptoms earlier and have more severe disease
• Exercise restriction reduces VT by 38%
• Even if you have the gene but no symptoms yet, exercise restriction delays when the disease appears

What's restricted:

• Banned: All competitive sports (this is a career-ending diagnosis for competitive athletes)
• Banned: Endurance sports (marathons, triathlons, intense cycling)
• Permitted: Low-moderate intensity recreational activities:
  • Walking, golf, recreational swimming, doubles tennis, light cycling
  • "Goal: Keep total exercise to less than 2000 MET-minutes/week (roughly 30 minutes of moderate activity 3 times per week)"

This is hard: Especially for athletes, this is life-changing. Support groups and counseling can help.

5. Family Screening — Essential

Because ARVC is genetic:

• All first-degree relatives (parents, siblings, children) should be screened with ECG, echocardiogram, Holter monitor, and ideally cardiac MRI
• Genetic testing: If we find your mutation, we can test your relatives. If they test negative, they don't have to worry. If positive, they need monitoring even if they feel fine.
• Screening should repeat every 2-5 years, because ARVC can develop over time (age-dependent penetrance)

What to expect long-term

Monitoring:

• ICD checks: Every 3-6 months (quick, painless check of the device)
• Imaging (echo or MRI): Every 1-3 years to track disease progression
• Holter monitor: Annually to check for new arrhythmias

Prognosis:

• With ICD and treatment: Most people live long, normal lives. 10-year survival is 85-95%
• Disease progression: ARVC is progressive—the right ventricle may continue to weaken, and the left ventricle may eventually be affected. If heart function becomes very weak, heart transplantation is an option (and works well—the transplanted heart doesn't have ARVC).

Pregnancy:

• Women with ARVC can have children, but pregnancy is high-risk
• Need close monitoring by cardiology + high-risk obstetrics
• Discuss with your doctor before planning pregnancy

Psychosocial:

• ARVC diagnosis can cause anxiety, depression, especially after ICD shocks
• Support groups (e.g., ARVC Foundation) are very helpful
• Discuss any psychological symptoms with your doctor

When to seek help

Call 999 / Emergency Services immediately if:

• You feel your ICD shock you (means it detected VT/VF—it may have saved your life, but you need evaluation)
• You faint or nearly faint
• You have sustained rapid palpitations that don't resolve
• You have chest pain with shortness of breath

Call your doctor if:

• New or worsening palpitations
• New swelling in your legs (may indicate worsening heart function)
• Concerns about your ICD (frequent beeping, battery alerts)

Key takeaways

1. ARVC is serious, but treatable. With an ICD, exercise restriction, and medications, most people do well.
2. The ICD is life-saving. If your doctor recommends one, it's because your risk of sudden death is significant without it.
3. Exercise restriction is not optional. It's hard, but it genuinely slows the disease and reduces dangerous rhythms.
4. Your family needs screening. ARVC runs in families—early diagnosis in relatives can save lives.
5. Stay connected with your care team. Regular monitoring is essential as the disease can progress.

Resources:

• ARVC Foundation: https://www.arvdinfo.com
• Johns Hopkins ARVC Program: Leading research and clinical center

---

13. Common Exam Questions & Viva Points

High-Yield MCQ Topics

1. Diagnostic criteria: Epsilon wave (major depolarization criterion); T wave inversion V1-V3 (minor repolarization)
2. Genetics: PKP2 most common mutation; autosomal dominant inheritance
3. ECG: VT with LBBB morphology + superior axis (RV origin)
4. ICD indications: Class I for cardiac arrest/sustained VT; Class IIa for syncope + high-risk features
5. Exercise restriction: Avoid competitive sports in all patients, even gene-positive/phenotype-negative

Viva Scenario

Examiner: "A 28-year-old competitive cyclist presents with recurrent palpitations during training. ECG shows T wave inversions in V1-V3. What's your differential and approach?"

Model Answer:

"This presentation raises concern for arrhythmogenic right ventricular cardiomyopathy, particularly given the age, athletic background, and characteristic ECG finding of T wave inversion in the right precordial leads.

Differential diagnosis includes:

1. ARVC (primary concern—leading cause of SCD in young athletes)
2. Athlete's heart (but TWI beyond V2 is unusual and concerning)
3. Acute myocarditis (would expect acute presentation, troponin elevation)
4. Brugada syndrome (would expect coved ST elevation, not TWI)
5. Idiopathic RVOT VT (structurally normal heart, excellent prognosis)

My approach would be systematic application of the 2010 Task Force Criteria:

1. History:

• Detailed symptom characterization (palpitations: regular vs irregular, duration, triggers)
• Exercise history (endurance training is a risk factor and accelerant)
• Family history—critical to ask about sudden death less than 35 years, known ARVC, unexplained drowning/accidents
• Syncope history (high-risk feature)

2. Investigations:

• 12-lead ECG: Already shows T wave inversion V1-V3 (minor repolarization criterion); look for epsilon wave (major criterion—pathognomonic), terminal activation delay
• Holter monitor (24-48 hours): Detect VT with LBBB morphology (major if superior axis), PVCs (minor if > 500/24h)
• Echocardiography: Assess RV size, function, regional wall motion abnormalities (akinesia/dyskinesia)
• Cardiac MRI (gold standard): Tissue characterization (fibro-fatty infiltration), late gadolinium enhancement (fibrosis), quantify RV volumes and ejection fraction
• Exercise test: May unmask exercise-induced VT
• Genetic testing: Desmosomal gene panel (PKP2, DSG2, DSP, DSC2, JUP)
• Family screening: First-degree relatives

3. Risk Stratification (if ARVC confirmed):

• Assess for high-risk features: syncope, sustained VT, severe RV/LV dysfunction, extensive MRI changes, high-risk genotype
• Calculate 5-year VT/VF risk (Cadrin-Tourigny calculator)
• Determine ICD indication

4. Management:

• Immediate: Disqualify from competitive cycling (Class I recommendation—this is career-ending)
• ICD: If high-risk features present (secondary prevention if sustained VT; primary prevention if syncope, severe dysfunction)
• Medical therapy: Beta-blocker (all patients); antiarrhythmics if recurrent VT
• Exercise restriction: Limit to recreational, low-moderate intensity (less than 2000 MET-min/week)
• Family cascade screening: ECG, echo, MRI, genetic testing of first-degree relatives

5. Prognosis: With ICD and exercise restriction, excellent prognosis; SCD risk reduced from 5-10% to less than 1% per year."

Examiner: "What would make you not diagnose ARVC?"

Model Answer: "I would reconsider if:

• Echocardiography and MRI are entirely normal (no structural abnormalities)—suggests idiopathic RVOT VT or athlete's heart
• T wave inversion regresses with 3 months detraining (suggests athlete's heart)
• Troponin elevation + acute presentation with wall motion abnormality that improves (myocarditis)
• No family history + isolated minor criteria (doesn't meet TFC)

However, I'd maintain high suspicion and serial imaging every 1-2 years if strong clinical concern, as ARVC has age-dependent penetrance."

Common Mistakes (What Fails Candidates)

❌ Failing to ask about family history of sudden death (essential for ARVC diagnosis and risk stratification) ❌ Diagnosing ARVC on MRI fat alone (not specific; must correlate with wall motion abnormalities and other TFC) ❌ Not recommending exercise restriction in athletes (this is non-negotiable, Class I recommendation) ❌ Using flecainide as monotherapy for VT (contraindicated in structural heart disease without beta-blocker) ❌ Forgetting family cascade screening (50% of first-degree relatives will carry mutation) ❌ Not recognizing ICD indications (cardiac arrest/sustained VT = Class I; some candidates inappropriately defer)

---

14. References

Primary Guidelines

1. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-2867. doi:10.1093/eurheartj/ehv316

2. Corrado D, Basso C, Judge DP. Arrhythmogenic Cardiomyopathy. Circ Res. 2017;121(7):784-802. doi:10.1161/CIRCRESAHA.117.309345

3. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373(9671):1289-1300. doi:10.1016/S0140-6736(09)60256-7

4. Smith ED, Lakdawala NK, Papoutsidakis N, et al. Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2020;141(23):1872-1884. doi:10.1161/CIRCULATIONAHA.119.044934

5. Corrado D, Zorzi A. Sudden death in athletes. Int J Cardiol. 2017;237:67-70. doi:10.1016/j.ijcard.2017.03.034

6. Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R. Clinical Diagnosis, Imaging, and Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Coll Cardiol. 2018;72(7):784-804. doi:10.1016/j.jacc.2018.05.065

7. Wichter T, Paul TM, Eckardt L, et al. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz. 2005;30(2):91-101. doi:10.1007/s00059-005-2677-6

8. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Circulation. 2010;121(13):1533-1541. doi:10.1161/CIRCULATIONAHA.108.840827

9. Corrado D, Anastasakis A, Basso C, et al. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report. Int J Cardiol. 2024;395:131447. doi:10.1016/j.ijcard.2023.131447

10. Malik N, Mukherjee M, Wu KC, et al. Multimodality Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy. Circ Cardiovasc Imaging. 2022;15(2):e013725. doi:10.1161/CIRCIMAGING.121.013725

11. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis. Circulation. 2015;132(22):e273-e280. doi:10.1161/CIR.0000000000000239

12. Platonov PG, Svensson A. Epsilon Waves as an Extreme Form of Depolarization Delay: Focusing on the Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Curr Cardiol Rev. 2021;17(1):17-23. doi:10.2174/1573403X16666200810105029

13. Wu S, Wang P, Hou Y, et al. Epsilon wave in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Pacing Clin Electrophysiol. 2009;32(1):59-63. doi:10.1111/j.1540-8159.2009.02176.x

14. Wang W, Orgeron G, Tichnell C, et al. Impact of Exercise Restriction on Arrhythmic Risk Among Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. J Am Heart Assoc. 2018;7(12):e008843. doi:10.1161/JAHA.118.008843

15. Wang W, Tichnell C, Murray BA, et al. Exercise restriction is protective for genotype-positive family members of arrhythmogenic right ventricular cardiomyopathy patients. Europace. 2020;22(8):1270-1278. doi:10.1093/europace/euaa105

16. Cadrin-Tourigny J, Bosman LP, Nozza A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019;40(23):1850-1858. doi:10.1093/eurheartj/ehz103

17. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16(11):e301-e372. doi:10.1016/j.hrthm.2019.05.007

18. Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation. 2006;113(13):1634-1637. doi:10.1161/CIRCULATIONAHA.105.616490

19. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(14):1290-1297. doi:10.1016/j.jacc.2013.06.033

20. van Lint FHM, Murray B, Tichnell C, et al. Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circ Genom Precis Med. 2019;12(8):e002467. doi:10.1161/CIRCGEN.119.002467

21. Hodgkinson KA, Howes AJ, Boland P, et al. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy. Circ Arrhythm Electrophysiol. 2016;9(3):e003589. doi:10.1161/CIRCEP.115.003589

22. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52(25):2175-2187. doi:10.1016/j.jacc.2008.09.019

23. Gasperetti A, Rossi VA, Chiodini A, et al. Differentiating hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis fulfilling 2010 ARVC Task Force Criteria. Heart Rhythm. 2021;18(2):231-238. doi:10.1016/j.hrthm.2020.09.015

24. Tandri H, Bomma C, Calkins H, Bluemke DA. Magnetic resonance and computed tomography imaging of arrhythmogenic right ventricular dysplasia. J Magn Reson Imaging. 2004;19(6):848-858. doi:10.1002/jmri.20078

25. Zorzi A, Rigato I, Bauce B, et al. Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy. Curr Cardiol Rep. 2016;18(6):57. doi:10.1007/s11886-016-0734-9

26. Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012;5(3):499-505. doi:10.1161/CIRCEP.111.968677

27. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-2867. doi:10.1093/eurheartj/ehv316

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and involve consultation with appropriate specialists. This information is not a substitute for professional medical advice, diagnosis, or treatment. Always consult qualified healthcare providers for patient-specific recommendations.